IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – March 15, 2022 – Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced the appointment of global commercial leader Elizabeth (Betsy) Hanna as Executive Vice President and Chief Commercial Officer, effective March 15, 2022. “We are pleased to welcome Betsy as a critical member of our executive team. Betsy is a distinguished global healthcare and biotech executive with a proven track record building market value in medical device and diagnostic businesses in the US and globally,” said Mark Straley, Chief Executive Officer of Agendia. “Her extensive functional Read More

January 27, 2022 By Leo O’Connor NEW YORK ─ As part of its effort to gain regulatory clearance in the US and beyond, Agendia has begun offering early access to a digital testing platform for patients in Brazil that allows physicians to receive genomic insights from a digitized image of a tumor to predict the likelihood of metastasis in early-stage breast cancer. The rollout aligns with Agendia's long-term goal to achieve broad, global adoption for tests in its pipeline and provide results from a hematoxylin and eosin (H&E) stain that are equivalent to the information provided by its current microarray-based MammaPrint assay, the firm said. The new digital assay, called Digital MammaPrint, uses artificial intelligence technology developed thorough a collaboration between Agendia and New Read More

New analysis in peer-reviewed journal Genes, Chromosomes and Cancer further establishes that MammaPrint and BluePrint both comprehensively represent and capture the 10 hallmarks of cancer in early-stage breast cancer Study validates genomic basis of MammaPrint High 2 category for breast cancer tumors, shows genomic testing can provide further details into biological significance and clinical behavior IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – February 7, 2022 – Agendia, Inc., a commercial stage company focused on enabling optimized decision-making by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients worldwide, today announced new data published in Genes, Chromosomes and Cancer (Genes) that show MammaPrint® and BluePrint® gene signatures represent and Read More

AI solution will expand Agendia’s testing platform in the Brazilian breast cancer market Digital MammaPrint offers fast turnaround time to molecular diagnostics, delivering actionable information to physicians treating patients with breast cancer IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 12, 2022 – Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced that it is offering early access to its Digital MammaPrint platform for patients with breast cancer in Brazil, expanding the company’s offerings in the country with the goal of bringing essential information from cancer testing to the larger global breast cancer community. Brazil is the first country to have samples analyzed by Digital MammaPrint, allowing physicians and their patients to benefit from Read More

Multi-year partnership to advance the use of next-generation sequencing for decentralized oncology testing, to bring improved insights to patients with breast cancer globally IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 10, 2022 – Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced a multi-year partnership with Illumina, Inc. (NASDAQ: ILMN), to co-develop in vitro diagnostic (IVD) tests for oncology testing. The partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing and aligns with Illumina’s approach to IVD partnerships in oncology. Agendia joins Illumina’s growing portfolio of more than 30 IVD partners developing over 40 sequencing-based solutions for cancer prognosis, therapy selection, and other applications. Illumina and Agendia Read More

IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – January 6, 2022 – Agendia, Inc., a commercial stage company focused on precision oncology for breast cancer, today announced the appointment of healthcare industry veterans Suja Chandrasekaran, MS and Scott Mendel, MBA to the Company’s Board of Directors. “We are pleased to be expanding Agendia’s Board of Directors with the appointment of two accomplished industry executives,” said Mark Straley, Chief Executive Officer of Agendia. “With combined decades of leadership and results-driven performance, Suja and Scott will provide Agendia with invaluable guidance, informed by extensive executive experience. As we continue to deliver on our goal to provide crucial genomic information to physicians and their patients to improve care, we look forward to tapping into Read More